AAHI Partners with Quratis to Accelerate Global Vaccine Development for Tuberculosis, Malaria, and HIV
核心洞察
Access to Advanced Health Institute (搜索) (AAHI (搜索)) has selected Quratis (搜索) as its preferred manufacturer for high-quality pre-clinical and clinical vaccine supplies targeting deadly diseases including tuberculosis (搜索), malaria (搜索), and HIV (搜索).
The partnership leverages Quratis (搜索)' GMP-certified bioplant and CDMO expertise to enable scalable, cost-effective production of AAHI (搜索)'s innovative vaccine formulations, including dry vaccines and needle-free delivery systems.
The collaboration builds on existing work including the co-development of the ID93+GLA-SE tuberculosis (搜索) vaccine candidate (QTP101) and aims to strengthen global vaccine supply chains for vulnerable populations.
Access to Advanced Health Institute (搜索) (AAHI (搜索)), a global leader in translating high-impact science into scalable vaccine solutions, has announced a strategic partnership with Quratis (搜索), a premier biotechnology company and advanced Contract Development and Manufacturing Organization (CDMO). The collaboration positions Quratis as AAHI's preferred manufacturer for high-quality pre-clinical and clinical vaccine supplies, with capacity to expand into commercial-scale production for global markets.
The partnership aims to accelerate development of AAHI (搜索)'s vaccine candidates targeting deadly diseases such as tuberculosis (搜索), and vaccines that rely on AAHI's vaccine adjuvants to provide protection against malaria (搜索), HIV (搜索), and other global health threats.
Manufacturing Capabilities and Innovation
Quratis (搜索) brings a world-class GMP-certified bioplant and cutting-edge CDMO expertise in biopharmaceutical raw material development, process optimization, and finished pharmaceutical manufacturing. The designation of Quratis as a preferred partner strengthens both AAHI (搜索)'s scientific capabilities and access to scalable, cost-effective production of groundbreaking vaccine formulations.
The collaboration enables production of innovative delivery systems, including dry vaccines that eliminate cold chain dependencies and needle-free delivery systems for superior respiratory protection. These technologies address critical logistical challenges in global vaccine deployment, particularly for vulnerable populations in resource-limited settings.
Strategic Vision and Leadership Perspectives
"Partnering with Quratis (搜索) is a very important step in AAHI (搜索)'s strategy to advance practical, life-saving vaccines, that can be deployed at scale where they're needed most," said Keeley Foley, CEO of AAHI. "Quartis' innovative cutting edge, safe, world-class CDMO capabilities makes it possible for AAHI to deliver on our mission – and helps ensure our efforts to combat infectious diseases and foster health autonomy worldwide."
Soung Joon Kim, CEO of Quratis (搜索), emphasized the alignment with the company's broader mission: "We are honored and thrilled to join forces with AAHI (搜索), a pioneer in immune-enhancing technologies and sustainable vaccine solutions. This partnership aligns perfectly with our vision of making people happy and healthy through borderless healthcare innovations. By supporting AAHI's pipeline, we expect to create value not only for global health, but also for our shareholders through long-term growth opportunities."
Existing Collaborations and Pipeline Development
The partnership builds on existing collaborations, including the co-development of the ID93+GLA-SE tuberculosis (搜索) vaccine candidate (QTP101). Quratis (搜索) has demonstrated expertise in vaccine development with a track record of success in TB and COVID-19 (搜索) vaccines, including QTP101 and QTP104.
The company's advanced processes are expected to enhance AAHI (搜索)'s pipeline, ensuring high-quality, efficient production from pre-clinical stages through clinical trials. Quratis (搜索) offers superior CDMO capabilities, including expertise in mRNA-LNP drug delivery platforms that provide seamless bench-to-field support from research through commercial production.
Global Health Impact and Supply Chain Strategy
The partnership ensures a seamless supply chain platform, enabling swift clinical development and broader deployment to the world's most vulnerable populations. The collaboration underscores a shared commitment to strengthening international vaccine supply chains, advancing equitable access, and fostering worldwide manufacturing capacity for sustainable program deployment.
Both organizations emphasize their focus on breaking through barriers in global health equity, with AAHI (搜索)'s mission centered on creating innovative vaccine formulations and building worldwide manufacturing capacity to ensure sustainable, equitable health outcomes.